Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS



Status:Recruiting
Conditions:Other Indications
Therapuetic Areas:Other
Healthy:No
Age Range:3 - 18
Updated:1/16/2019
Start Date:November 9, 2018
End Date:September 30, 2020
Contact:Nancy Tich, PhD
Email:tichn@zynerba.com
Phone:973-727-4117

Use our guide to learn which trials are right for you!

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome - CONNECT-FX Open Label Extension (OLE)

ZYN002 is a pharmaceutically manufactured Cannabidiol (CBD) that is developed as a clear gel
that can be applied to the skin (called transdermal delivery).

The gel will be applied to clean, dry, intact skin of the shoulders and/or upper arms.

Only participants from the ZYN2-CL-016 study who meet the inclusion criteria and none of the
exclusion criteria for study ZYN2-CL-017 are eligible.

Parents/caregivers will apply the study gel twice daily for the 52-week treatment period.

This is an open-label extension, multiple-center study, to assess the long-term safety and
tolerability of CBD administered as ZYN002, a transdermal gel, for the treatment of child and
adolescent patients with Fragile X Syndrome (FXS). Male and female patients with FXS will be
treated for up to 12 months. Up to 300 male and female patients, ages 3 to 18 years will be
enrolled.

Parents/caregivers will apply the study gel twice daily for the 52-week treatment period.

Participants who weigh less than or equal to 35 kg, will receive 1 sachet of ZYN002, applied
every 12 hours (± 2 hours).

Participants who weigh more than 35 kg will receive 2 sachets of ZYN002, applied every 12
hours (± 2 hours).

At the Investigator's discretion, the dose may be increased to a total of 4 sachets a day or
decreased to a total of 2 sachets a day any time after the first month of treatment.

Participants whose weight changes during the course of the study may have their doses changed
at the investigator's discretion on or after the Month 1 visit, or reduced due to
tolerability issues at investigator's discretion.

Participants who are taking anti-epileptic drugs may have an additional one or two weeks of
treatment after the 52 week treatment period to taper off study treatment.

Blood samples will be collected for safety analysis of ZYN002. Additionally, the
parents/caregivers will be asked to complete some questionnaires. There will be other
questionnaires and scales that will be completed at the site by the study doctor and/or with
the participant and their parents/caregivers.

Inclusion Criteria:

- Participated in the ZYN2-CL-016 study.

- Patients and parents/caregivers agree to abide by all study restrictions and comply
with all study procedures.

- Patients and parents/caregivers must be adequately informed of the nature, risks of
the study, and give written informed consent prior to enrollment in ZYN2-CL-017.

- In the Investigator's opinion, the patients and parents/caregivers are reliable and
are willing and able to comply with all protocol requirements and procedures.

- Females of childbearing potential must have a negative pregnancy test at all
designated visits

Exclusion Criteria:

- Patient is receiving any investigational drugs (not ZYN002) or using any experimental
devices.

- Patient has an ongoing serious adverse event (SAE) or has experienced a SAE in
ZYN2-CL-016, which in the opinion of the Investigator, should exclude them from
participation.

- Females who are pregnant, nursing, or planning a pregnancy; females of childbearing
potential and male patients with a partner of childbearing potential who are unwilling
or unable to use an acceptable method of contraception for the duration of therapy and
for three months after the last dose of trial drug.

- Patients who have alanine aminotransferase (ALT), aspartate aminotransferase (AST), or
total bilirubin levels >= 2 times the upper limit of normal (ULN) or has alkaline
phosphatase levels >= 3 times the ULN as determined from patient safety laboratories.
We found this trial at
18
sites
Media, Pennsylvania 19063
?
mi
from
Media, PA
Click here to add this to my saved trials
1648 Pierce Dr NE
Atlanta, Georgia 30322
(404) 727-5640
Emory University School of Medicine Emory University School of Medicine has 2,359 full- and part-time...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
707 North Broadway
Baltimore, Maryland 21205
443-923-9200
Kennedy Krieger Institute While not officially part of Johns Hopkins Medicine, Kennedy Krieger Institute is...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Denver, Colorado 80045
?
mi
from
Denver, CO
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Morristown, New Jersey 07960
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
1919 E Thomas Rd
Phoenix, Arizona 85006
(602) 933-1000
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Sacramento, California 95817
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Staten Island, NY
Click here to add this to my saved trials
Sydney, New South Wales
?
mi
from
Sydney,
Click here to add this to my saved trials
Tulsa, Oklahoma 74136
Principal Investigator: Sarah Land, MD
Phone: 918-645-5400
?
mi
from
Tulsa, OK
Click here to add this to my saved trials